| Cadence Pharmaceuticals, Inc. Q1 2010 Earnings Call Transcript Cadence Pharmaceuticals, Inc. (CADX)Q1 2010 Earnings Call TranscriptMay 6, 2010 4:30 pm ETComplete Story » seekingalpha.com |
New York Hospitals Extend Hours As demand has increased, several hospitals in New York are offering outpatient hospital care late into the night or on Saturdays to alleviate weekday crowding. online.wsj.com |
Antigenics: Bright Future Ahead VFC submits: Shares of Antigenics (AGEN) approached the one dollar mark during Tuesday's trading session after the company released a positive update regarding a Phase I trial for AG-707, a potential treatment for herpes simplex virus-2 (HSV-2), the virus that causes genital herpes. AG-707, if it works as advertised, is not a cure for the disease, but could help in treatment and prevention.Phase I results come too soon in a pipeline to get really excited about when looking at the short to mid term, but the early success of this product only adds to the potentially bright future of Antigenics. Complete Story » seekingalpha.com |
Hedge Fund Manager Takes Bid Directly to Cypress Shareholders The Burrill Report submits: By Michael FitzhughRamius, a hedge fund manager trying to gain control of Cypress Bioscience (CYPB), is taking its $148 million hostile bid directly to Cypress shareholders, bypassing the company's management after it rejected a lower bid in August. Complete Story » seekingalpha.com |
Biotech ETFs: The Better Way to Play Tom Lydon submits: As cash-strapped biotech companies see their cash reserves dwindle, it has forced a number of companies to close up shop. The struggles faced in the sector highlights the benefits of getting exposure to it through biotech ETFs. The number of publicly-traded U.S. biotech companies has diminished by 25% since 2007, writes Brett Chase for Minyanville. The Biotechnology Industry Organization reported that of the 131 companies that had enough cash to fund a year’s worth of operations, 10 were acquired and 19 closed down. The other 102 are still around because of layoffs, private funding, secondary offerings and licensing early-stage experimental drugs.Complete Story » seekingalpha.com |